Clinical Trial: NCT02003222
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-11-13 |
Study Overview
Brief Summary
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.
Official Title
Conditions
Intervention / Treatment
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- Procedure: Biospecimen Collection
- Biological: Blinatumomab
- Procedure: Bone Marrow Aspiration
- Procedure: Bone Marrow Biopsy
- Drug: Cyclophosphamide
- Drug: Cytarabine
- Drug: Daunorubicin
- Drug: Daunorubicin Hydrochloride
- Drug: Dexamethasone
- Drug: Etoposide
- Drug: Leucovorin Calcium
- Procedure: Lumbar Puncture
- Drug: Mercaptopurine
- Drug: Methotrexate
- Drug: Pegaspargase
- Drug: Prednisone
- Biological: Rituximab
- Drug: Vincristine
- Drug: Vincristine Sulfate
- Procedure: X-Ray Imaging
Other Study ID Numbers
- NCI-2013-02229
- NCI-2013-02229
- ECOG-E1910
- PE1910_A08PAMDREVW01
- E1910
- E1910
- U10CA021115
- U10CA180820
- U24CA196172
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-11-13 |
Study Overview
Brief Summary
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.
Official Title
Conditions
Intervention / Treatment
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- Procedure: Biospecimen Collection
- Biological: Blinatumomab
- Procedure: Bone Marrow Aspiration
- Procedure: Bone Marrow Biopsy
- Drug: Cyclophosphamide
- Drug: Cytarabine
- Drug: Daunorubicin
- Drug: Daunorubicin Hydrochloride
- Drug: Dexamethasone
- Drug: Etoposide
- Drug: Leucovorin Calcium
- Procedure: Lumbar Puncture
- Drug: Mercaptopurine
- Drug: Methotrexate
- Drug: Pegaspargase
- Drug: Prednisone
- Biological: Rituximab
- Drug: Vincristine
- Drug: Vincristine Sulfate
- Procedure: X-Ray Imaging
Other Study ID Numbers
- NCI-2013-02229
- NCI-2013-02229
- ECOG-E1910
- PE1910_A08PAMDREVW01
- E1910
- E1910
- U10CA021115
- U10CA180820
- U24CA196172